Q-omics provides the consensus-scored C1orf56 profile across patient tissues and cancer cell-line models. C1orf56 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, C1orf56 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, C1orf56 RNA expression shows 18,440 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KICH, and ACC as cancer lineages where C1orf56 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1orf56 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1orf56 survival associations across molecular data types. C1orf56 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1orf56 RNA expression–survival associations across cancer types. High C1orf56 expression shows unfavorable associations in UVM, KIRC, COAD, ACC and STAD, but favorable associations in LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for C1orf56 RNA expression.
This table summarizes C1orf56 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for C1orf56. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1orf56 shows lower tumor expression in KICH, KIRC and THCA and higher tumor expression in LUAD, LIHC and COAD. The KICH box plot shows higher C1orf56 RNA expression in normal versus tumor tissue (log2 FC = −1.082, t-test p < 0.001).
This table shows molecular features associated with C1orf56 in patient tissues and cancer cell lines. In patient samples, C1orf56 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C1orf56 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and OVARY.
